The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Authors
Cook, GAshcroft, A
Cairns, D
Williams, C
Brown, J
Cavenagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Hunter, H
Bird, J
Pratt, G
Chown, S
Heartin, E
O'Connor, S
Drayson, M
Hockaday, A
Morris, T
Affiliation
Leeds Institute of Cancer & Pathology, University of Leeds, LeedsIssue Date
2016-07
Metadata
Show full item recordAbstract
The Myeloma X trial previously reported improved durability of response (time to disease progression) in patients with relapsed multiple myeloma with salvage autologous stem-cell transplantation (ASCT) compared with oral cyclophosphamide in patients with multiple myeloma relapsing after a first ASCT. We report the final overall survival results of the trial.Citation
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. 2016, 3 (7):e340-51 Lancet HaematolJournal
The Lancet. HaematologyDOI
10.1016/S2352-3026(16)30049-7PubMed ID
27374467Type
ArticleLanguage
enISSN
2352-3026ae974a485f413a2113503eed53cd6c53
10.1016/S2352-3026(16)30049-7